
Taysha Gene Therapies Inc
NASDAQ:TSHA

Intrinsic Value
The intrinsic value of one
TSHA
stock under the Base Case scenario is
0.78
USD.
Compared to the current market price of 2.38 USD,
Taysha Gene Therapies Inc
is
Overvalued by 67%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Taysha Gene Therapies Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Taysha Gene Therapies Inc
Balance Sheet Decomposition
Taysha Gene Therapies Inc
Current Assets | 120.7m |
Cash & Short-Term Investments | 116.6m |
Other Current Assets | 4.1m |
Non-Current Assets | 17.7m |
PP&E | 15.3m |
Other Non-Current Assets | 2.3m |
Free Cash Flow Analysis
Taysha Gene Therapies Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Taysha Gene Therapies Inc
Revenue
|
7.2m
USD
|
Operating Expenses
|
-95.8m
USD
|
Operating Income
|
-88.6m
USD
|
Other Expenses
|
1.8m
USD
|
Net Income
|
-86.8m
USD
|
TSHA Profitability Score
Profitability Due Diligence
Taysha Gene Therapies Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Score
Taysha Gene Therapies Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
TSHA Solvency Score
Solvency Due Diligence
Taysha Gene Therapies Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Score
Taysha Gene Therapies Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TSHA Price Targets Summary
Taysha Gene Therapies Inc
According to Wall Street analysts, the average 1-year price target for
TSHA
is 8.02 USD
with a low forecast of 5.05 USD and a high forecast of 13.65 USD.
Dividends
Current shareholder yield for TSHA is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
TSHA
stock under the Base Case scenario is
0.78
USD.
Compared to the current market price of 2.38 USD,
Taysha Gene Therapies Inc
is
Overvalued by 67%.